Carfilzomib: A novel second-generation proteasome inhibitor

Future Oncology

Volumn 7, Issue 5, 2011, Pages 607-612

  Khan, Meaghan L ^a   Stewart, A Keith ^a  

^a MAYO CLINIC   (United States)

Author keywords

bortezomib; carfilzomib; chymotrypsin like; multiple myeloma; PR 171; proteasome inhibitor

Indexed keywords

BORTEZOMIB; CARFILZOMIB; DEXAMETHASONE;

ACUTE GRANULOCYTIC LEUKEMIA; AMYLOIDOSIS; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; HUMAN; HYPOXIA; IMMUNOMODULATION; LARGE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MYELOMA; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR XENOGRAFT; URINARY TRACT INFECTION; VOMITING; WALDENSTROEM MACROGLOBULINEMIA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; HEMATOLOGIC NEOPLASMS; HUMANS; MULTIPLE MYELOMA; NEUTROPENIA; OLIGOPEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PYRAZINES; THROMBOCYTOPENIA;

EID: 79956071998     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.42     Document Type: Article

References (36)

1. Kyle RA, Rajkumar SV: Multiple myeloma. N. Engl. J. Med. 351, 1860-1873 (2004).
2. Rajkumar SV, Kyle RA: Plasma Cell Disorders. In: Cecil Textbook of Medicine (23rd Edition). Goldman L, Ausiello D (Eds). Saunders, Philadelphia, PA, USA 1426-1437 (2007).
3. Kumar SK, Rajkumar SV, Dispensieri A, et al.: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111, 2516-2520 (2007).
4. Ciechanover A: Proteolysis from the lysosome to ubiquitin and the proteasome. Nat. Rev. Mol. Cell Biol. 6, 79-87 (2005).
5. Dalton WS: The proteasome. Semin. Oncol. 31, 3-9 (2004). (Pubitemid 40164924)
6. Kisselev AF, Goldberg AL: Proteasome inhibitors from research tools to drug candidates. Chem. Biol. 8, 739-758 (2001). (Pubitemid 32752454)
7. Adams J: The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 4, 349-360 (2004). (Pubitemid 38579481)
8. Kuhn DJ, Hunsucker SA, Chen Q, et al.: Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 113, 4667-4676 (2009).
9. Parlati F, Lee SJ, Aujay M, et al.: Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 114, 3439-3447 (2009).
10. Kisselev AF, Goldberg AL: Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods Enzymol. 398, 364-378 (2005). (Pubitemid 41578898)
11. Rock KL, Gramm C, Rothstein L, et al.: Inhibitors of the proteasome block the degradation of most cell proteins and the generations of peptides presented on most MHC class I molecules. Cell 78, 761-771 (1994). (Pubitemid 24294452)
12. Demo SD, Kirk CJ, Aujay MA, et al.: Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 67(13), 6383-6391 (2007). (Pubitemid 47037522)
13. Adams J: The development of proteasome inhibitors as anticancer drugs. Cancer Cells 5, 417-421 (2004). (Pubitemid 38610244)
14. Adams J, Behnke M, Chen S, et al.: Potent and selective inhibitors of the proteasome; dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. 8, 333-338 (1998). (Pubitemid 28072702)
15. Richardson PG, Sonneveld P, Schuster MW, et al.: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352, 2487-2498 (2005). (Pubitemid 41007864)
16. Richardson PG, Briemberg H, Jaggannath S, et al.: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J. Clin. Oncol. 24, 3113-3120 (2006). (Pubitemid 46638949)
17. Lonial S, Walker EK, Richardson PG, et al.: Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 106, 3777-3784 (2005). (Pubitemid 41739012)
18. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al.: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 20, 4420-4427 (2002). (Pubitemid 35334752)
19. Papandreou CN, Daliani DD, Nix D, et al.: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J. Clin. Oncol. 22, 2108-2121 (2004). (Pubitemid 41095144)
20. Kuhn DJ, Chen Q, Voorhees PM, et al.: Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, agains preclinical models of multiple myeloma. Blood 110(9), 3281-3290 (2007). (Pubitemid 350106321)
21. Groll M, Kim KB, Kaires N, Huber R, Crews CM: Crystal structure of epoxymicin:20S proteasome reveals a molecular basis of a b-epoxyketone proteasome inhibitors. J. Am. Chem. Soc. 122, 1237-1238 (2000). (Pubitemid 30117471)
22. OConnor OA, Stewart AK, Vallone M, et al.: A Phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin. Cancer Res. 15(22), 7085-7091 (2009).
23. Dasmahapatra G, Lembersky D, Freidberg JW, et al.: Histone deacetylase inhibitors potentiate the lethality of the irreversible proteasome inhibitor carfilzomib in mantle cell lymphoma cells in vitro and in vivo. Blood 116 (2010) (Abstract 3938).
24. Gu J, Hernandez-Ilizaliturri FJ, Kaufman GP, et al.: Carfilzomib (CFZ): a novel proteasome inhibitor that induces cell cycle arrest and cell death in rituximab-chemotherapy resistant lymphoma and potentiates the anti-tumor activity of chemotherapeutic agents. Blood 116 (2010) (Abstract 4908).
25. Sacco A, Roccaro AM, Aujay M, et al.: Carfilzomib exerts anti-neoplastic activity in Waldenstrom macroglobulinemia. Blood 114 (2009) (Abstract 4916).
26. Alsina M, Trudel S, Vallone M, et al.: Phase I single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies. Blood 110 (2007) (Abstract 411).
27. Jagannath S, Vij R, Stewart AK, et al.: Initial results of PX-171-003, an open-label, single-arm, Phase II study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma (MM). Blood 112 (2008) (Abstract 864).
28. Vij R, Wang M, Orlowski R, et al.: Initial results of PX-171-004, an open-label, single-arm, Phase II study of carfilzomib (CFZ) in patients with relapsed myeloma (MM). Blood 112 (2008) (Abstract 865).
29. Seigel D, Wang L, Orlowski RZ, et al.: PX-171-004, an ongoing open-label, Phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM); updated results from the bortezomib-treated cohort. Blood 114 (2009) (Abstract 303).
30. Wang L, Seigel D, Kaufman JL, et al.: Updated results of bortezomib-nave patients in PX-171-004, an ongoing open-label, Phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM). Blood 114 (2009) (Abstract 302).
31. Vij R, Kaufman JL, Jakubowiak AJ, et al.: Carfilzomib: high single agent response rate with minimal neuropathy even in high risk patients. Blood 116 (2010) (Abstract 1938).
32. Jagannath S, Vij R, Somlo SG, et al.: Final results of PX-171-003-A0, part 1 of an open-label, single-arm, Phase II study on carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). J. Clin. Oncol. 27(Suppl. 15) (2009) (Abstract 8504).
33. Niesvizky R, Wang L, Orlowski RZ, et al.: Phase Ib multicenter dose escalation study of carfilzomib plus lenalidomide and low dose dexamethasone (CRd) in relapsed and refractory multiple myeloma (MM). Blood 114 (2009) (Abstract 304).
34. Jakubowiak AJ, Dytfeld D, Jagannath S, et al.: Carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma: initial results of Phase I/II MMRC trial. Blood 116 (2010) (Abstract 862).
35. Kirk CJ, Jiang J, Muchamuel T, et al.: The selective proteasome inhibitor carfilzomib is well tolerated in experimental animals with dose intensive administration. Blood 112 (2008) (Abstract 2765).
36. Papadopoulous K, Samuel diCapua Siegel D, Singhal SB, et al.: Phase 1b evaluation of the safety and efficacy of a 30-minute IV infusion of carfilzomib in patients with relapsed and/or refractory multiple myeloma. Blood 116 (2010) (Abstract 3024).